6th Edition of Global Conference on
Addiction Medicine, Behavioral Health and Psychiatry
October 20-22, 2025 | Orlando, Florida, USA
Opioid Agonist Therapy
Opioid Agonist Therapy (OAT) is a widely used treatment for opioid use disorder (OUD), where medications such as methadone or buprenorphine are used to mimic the effects of opioids in a controlled manner. OAT helps reduce withdrawal symptoms and cravings while blocking the euphoric effects of illicit opioid use. By stabilizing brain chemistry, OAT allows individuals to focus on recovery without the constant compulsion to seek out drugs. This approach has been shown to improve long-term outcomes by reducing the risk of overdose, preventing relapse, and enabling individuals to participate more fully in therapeutic interventions. OAT is often combined with counseling, support groups, and other psychosocial treatments to address the behavioral aspects of addiction.
Nile Stanley
University of North Florida, United States
Ann Marie Leonard Zabel
Curry College, United States
Denis Larrivee
University of Navarra, Spain
Scharbach Hugues
Paris University, France
Alphonsus Obayuwana
Triple-H Project LLC, United States
Malasri Chaudhery Malgeri
Recovery com, United States
Jana Furstova
Palacký University Olomouc, Czech RepublicSubmit your abstract Today
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : The A-B-C of happiness coaching
Alphonsus Obayuwana, Triple-H Project LLC, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Trait-based recovery: Evidence-based trait activation to reduce depression, anxiety, and improve client engagement in addiction treatment
Jason Glenn Roop, The Center for Trait-Based Transformation, United States
Title : An investigation of the factors responsible for ubstance abuse from a cognitive perspective based on a mixed method approach
Adewole Olukorede, Literary Edifice, Italy
Title : A Long-Acting Naltrexone Implant (for Opioid Use Disorder: First-in-Human Phase I Trial)
Steven M Cohen, Akyso Therapeutics, United States